drugset / Trial / NCT03853421
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
RandomizedSingle-groupQuadruple-blindTreatment
Summary
A Double-blind, Placebo-controlled study in Healthy Volunteers to Determine the Safety and Tolerability of Single, Ascending Subcutaneous Doses of Sevuparin
Timeline
- Start
- 2019-02-06
- Primary completion
- 2019-05-06
- Completion
- 2019-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sevuparin | Other / unclassified | 3 mg/kg | Subcutaneous |
| Subject | Sevuparin | Other / unclassified | 6 mg/kg | Subcutaneous |
| Subject | Sevuparin | Other / unclassified | 9 mg/kg | Subcutaneous |
Indications
No indication recorded.